Literature DB >> 32543459

Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice.

Abimbola Chris-Olaiya1, William Palmer2, Fernando Stancampiano3, Brian Lacy2, Michael Heckman4, Razvan Chirila3, Naveed Nikpour5, Ethan Mcleod5, Taylor Ryan5, Alex Maillis5, Emily Vargas4, Ernest Bouras2.   

Abstract

Introduction. Commonly prescribed medications are associated with various gastrointestinal (GI) side effects but few data are available on prescription medication use and polypharmacy in a gastroenterology outpatient practice. We aimed to examine the prevalence of polypharmacy, defined as the simultaneous use of 5 or more medications.Methods. A descriptive correlational study of consecutive outpatient consultations in 988 patients referred to a tertiary gastroenterology practice. Main outcome measurements were frequency of prescription medication use and polypharmacy.Results. The most common GI symptoms were abdominal pain (72%), nausea (57%), and constipation (53%). The frequency of polypharmacy was 10%. Eighty percent of patients took at least one medication and 60% took two or more. The most frequently used medication classes were proton pump inhibitors (43%), followed by benzodiazepines (30%), selective serotonin-reuptake or norepinephrine-reuptake inhibitors (28%), non-steroidal anti-inflammatory drugs (27%), and opioids (21%).Conclusion. There was a higher use of prescription medicine including antidepressants, and a lower frequency of polypharmacy in our study cohort compared to the general population. The use of medications may have contributed to the symptoms leading to our study's population GI consultation.
© 2020 Abimbola Chris-Olaiya et al., published by Sciendo.

Entities:  

Keywords:  adverse effects; gastrointestinal; polypharmacy; prescription medicine

Year:  2020        PMID: 32543459     DOI: 10.2478/rjim-2020-0016

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  1 in total

1.  Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran.

Authors:  Ali Ardekani; Pooran Mohsenzadeh; Hossein Poustchi; Zahra Mohammadi; Seyed Reza Abdipour Mehrian; Hamed Bazrafshan Drissi; Zahra Rahimian; Erfan Taherifard; Ali Nabavizadeh; Alireza Kamalipour; Bita Mesgarpour; Fatemeh Malekzadeh; Hossein Molavi Vardanjani
Journal:  BMC Cardiovasc Disord       Date:  2022-10-06       Impact factor: 2.174

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.